Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...

Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $16.9 which represents a decrease of $-1.00 or -5.59% from the prior close of $17.9. The stock opened at $18.15 and touched a ...

The market didn't like what this stock had to say this morning... The post Why did this $1.4 billion ASX 200 healthcare stock ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) and keeping the price ...

Annals of Family Medicine is proud to announce the early online publication of four impactful articles focusing on artificial intelligence (AI) and its role in primary care. These articles, now ...

Auquan, the market leader in AI agents for deep work in financial services, today announced record growth for 2024, marked by significant enterprise adoption, strategic product launches, and the ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...